CN1291735C - A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain - Google Patents
A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain Download PDFInfo
- Publication number
- CN1291735C CN1291735C CN 200410080445 CN200410080445A CN1291735C CN 1291735 C CN1291735 C CN 1291735C CN 200410080445 CN200410080445 CN 200410080445 CN 200410080445 A CN200410080445 A CN 200410080445A CN 1291735 C CN1291735 C CN 1291735C
- Authority
- CN
- China
- Prior art keywords
- ethanol
- extract
- thick paste
- filtrate
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000006187 pill Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 210000004369 blood Anatomy 0.000 title description 8
- 239000008280 blood Substances 0.000 title description 8
- 230000001737 promoting effect Effects 0.000 title description 8
- 208000002193 Pain Diseases 0.000 title description 4
- 230000017531 blood circulation Effects 0.000 title description 4
- 230000036407 pain Effects 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 124
- 239000000284 extract Substances 0.000 claims abstract description 45
- 239000000706 filtrate Substances 0.000 claims abstract description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 27
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 20
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 238000003860 storage Methods 0.000 claims abstract description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract 4
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract 4
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract 4
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract 4
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract 4
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 3
- 239000012046 mixed solvent Substances 0.000 claims abstract 2
- 238000010992 reflux Methods 0.000 claims description 18
- 238000005325 percolation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 241001092040 Crataegus Species 0.000 claims 3
- 235000010575 Pueraria lobata Nutrition 0.000 claims 3
- 244000046146 Pueraria lobata Species 0.000 claims 3
- 244000132619 red sage Species 0.000 claims 3
- 239000000469 ethanolic extract Substances 0.000 claims 2
- 239000003205 fragrance Substances 0.000 claims 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000010365 xinkeshu Substances 0.000 abstract description 30
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 241001226044 Salvia pachyphylla Species 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 42
- 229940079593 drug Drugs 0.000 description 26
- 241000700159 Rattus Species 0.000 description 25
- 239000012567 medical material Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 208000031225 myocardial ischemia Diseases 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 206010003119 arrhythmia Diseases 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000006793 arrhythmia Effects 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000001035 drying Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 7
- 108010042126 Creatine kinase Proteins 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000001631 hypertensive effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 5
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 5
- 229940039750 aconitine Drugs 0.000 description 5
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 5
- 238000003810 ethyl acetate extraction Methods 0.000 description 5
- -1 filtration Substances 0.000 description 5
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000005622 photoelectricity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 150000003673 urethanes Chemical class 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003896 aconitine group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种新的中药制剂心可舒滴丸制剂，该滴丸制剂是采用新的工艺制备的，该工艺包括以下步骤：步骤a.山楂、葛根、三七用乙醇提取，提取液过滤，滤液备用；步骤b.丹参用乙醇或水提取，提取液滤过得滤液；步骤c.步骤b与步骤a得到的滤液合并，浓缩，以醋酸乙酯或乙醇和醋酸乙酯的混合溶剂萃取，萃取液浓缩，得稠膏或干燥粉末；步骤d.木香粉碎用乙醇作溶剂，浸泡，渗漉，渗漉液回收乙醇，浓缩成稠膏；步骤e.将步骤c得到的稠膏或干燥粉末加入已熔融的聚乙二醇中，再加步骤d得到的稠膏，搅匀，将药液置滴丸机贮料罐中，用滴丸机制成滴丸。The present invention relates to a new traditional Chinese medicine Xinkeshu drop pill preparation, which is prepared by a new process, and the process includes the following steps: Step a. Extract Hawthorn, Radix Puerariae and Panax notoginseng with ethanol, and filter the extract , the filtrate is standby; Step b. Salvia miltiorrhiza is extracted with ethanol or water, and the extract is filtered to obtain the filtrate; Step c. The filtrate obtained in step b and step a is combined, concentrated, and extracted with ethyl acetate or a mixed solvent of ethanol and ethyl acetate , the extract is concentrated to obtain a thick paste or dry powder; step d. the woody incense is crushed with ethanol as a solvent, soaked, percolated, and the ethanol is recovered from the percolated liquid, and concentrated into a thick paste; step e. the thick paste obtained in step c or Add the dry powder into the molten polyethylene glycol, add the thick paste obtained in step d, stir well, put the medicine liquid in the storage tank of the dropping pill machine, and use the dropping pill machine to make dropping pills.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation, particularly a kind of blood circulation promoting and blood stasis dispelling, the Chinese medicine dripping pills preparation of promoting the circulation of QI to relieve pain, this dropping pill formulation are to adopt new prepared.
Background technology:
XINKESHU PIAN be Shandong China Wo Medicine Co according to the seventies well-known doctor's proved recipe develop voluntarily; now record in the 16 (protection fascicle) the 24th page of " Drug Standard of Ministry of Public Health of the Peoples Republic of China " Chinese traditional patent formulation preparation, XINKESHU PIAN is national essential drug kind, national medical insurance kind, national Chinese medicine protection kind.XINKESHU PIAN is made up of Radix Salviae Miltiorrhizae, Radix Puerariae, Fructus Crataegi, Radix Notoginseng, the Radix Aucklandiae, has blood circulation promoting and blood stasis dispelling, the effect of promoting the circulation of QI to relieve pain.Diseases such as clinical uncomfortable in chest, the angina pectoris that is used for that qi stagnation blood stasis type coronary heart disease causes, hypertension, dizziness, headache, neck pain and arrhythmia, hyperlipidemia.This product determined curative effect, toxic and side effects is few, is subjected to the welcome of vast patients with coronary heart disease deeply.
Along with the continuous development of science and technology and improving constantly of new drug development level, the continuous application of new theory, new technique, new technology, new equipment, XINKESHU PIAN is not in full conformity with the requirement of the modernization of Chinese medicine.Mainly direct pulverizing of part crude drug is used as medicine in the side of showing, dose is big, and bioavailability is low, and the drug effect performance is slower.For overcoming the deficiency of XINKESHU PIAN, preparation reaches the curative effect height, dosage is little, toxic and side effects is little in line with making, accumulating portably uses purpose easily, and on the prescription basis of XINKESHU PIAN, the present invention is improved to drops through technological transformation with XINKESHU PIAN.But heart drop pills preparation of the present invention, drug absorption is fast, and produce effects is rapid, the bioavailability height, preparation technology is simple, and dose is few, and very suitable patients with coronary heart disease medication selects for use drops can satisfy the demand of patients with coronary heart disease better.
Summary of the invention:
The present invention has carried out technological transformation to XINKESHU PIAN, by being extracted with new technology, Chinese medicine of the five flavours such as Radix Salviae Miltiorrhizae, Radix Puerariae, Fructus Crataegi, Radix Notoginseng, the Radix Aucklandiae obtain new extract, be active constituents of medicine further again with this extract, the new pharmaceutical preparation of making: dropping pill formulation.
Its prescription of dropping pill formulation of the present invention is composed as follows:
Radix Puerariae 500～800g, Fructus Crataegi 400～800g, Radix Salviae Miltiorrhizae 400～800g, Radix Notoginseng 20～60g, the Radix Aucklandiae 20～60g.
Preferably:
Radix Puerariae 600～800g, Fructus Crataegi 500～700g, Radix Salviae Miltiorrhizae 500～700g, Radix Notoginseng 30～50g, the Radix Aucklandiae 30～50g.
More preferably:
Radix Puerariae 600g Fructus Crataegi 600g Radix Salviae Miltiorrhizae 600g Radix Notoginseng 40g Radix Aucklandiae 40g
More than the prescription composition can be made pharmaceutical preparation: 10000 of drop pill.
The present invention also comprises, Chinese medicine extract made from above prescription and preparation method thereof.
The preparation method of Chinese medicine extract of the present invention may further comprise the steps:
Get Radix Salviae Miltiorrhizae, Radix Puerariae, Fructus Crataegi, Radix Notoginseng, Radix Aucklandiae Chinese medicine of the five flavours material,
Step a: wherein Fructus Crataegi, Radix Puerariae, Radix Notoginseng are used ethanol extraction, extracting liquid filtering, filtrate for later use;
Step b: Radix Salviae Miltiorrhizae ethanol or water extraction, extracting solution filter filtrate;
The filtrate that step c: step b and step a obtain merges, and concentrates, and with the mixed extractant solvent of ethyl acetate or ethanol and ethyl acetate, extract concentrates, and gets thick paste or dried powder;
Steps d: the Radix Aucklandiae is pulverized and is made solvent with ethanol, soaks, and percolation, percolate reclaims ethanol, is condensed into thick paste;
Preferably can adopt following steps:
Step a: Fructus Crataegi, Radix Puerariae, Radix Notoginseng, measure 40～80% alcohol reflux 2 times for 3～10 times with each medical material, 1～3 hour for the first time, 1～3 hour for the second time, merge alcohol extract, reclaim ethanol, filtration, filtrate for later use;
Step b: Radix Salviae Miltiorrhizae extracts three times, adds 60～95% alcohol refluxs 1～3 hour of 3～15 times of amounts of medical material for the first time, filters, and filtrate recycling ethanol is to there not being the alcohol flavor; Add for the second time 20～80% alcohol refluxs 1～3 hour of 3～15 times of amounts, filter, reclaim ethanol; The water that adds 3～15 times of amounts of medical material for the third time refluxed 1～3 hour, filtered merging filtrate;
Step c: merge with the standby filtrate of step a, being evaporated to relative density jointly is the clear paste of 1.06-1.12 (80 ℃ of surveys), with 10～60% alcoholic acid ethyl acetate extractions of the ethyl acetate of equimultiple or equimultiple 3～6 times, combining extraction liquid, and concentrating under reduced pressure becomes thick paste, or with thick paste in 60～80 ℃ of dryings 8 hours, pulverize, cross 80 mesh sieves, get dried powder;
Steps d: Radix Aucklandiae powder is broken into coarse powder, according to " percolation is made solvent with 60～95% ethanol under Chinese pharmacopoeia appendix 20 fluid extracts of version in 2000 and the extractum item, soaks after 24 hours, and percolation, percolate reclaim the ethanol concentrating under reduced pressure and become thick paste;
Thick paste that step c and steps d obtain or dry powder are exactly extract of the present invention, and this extract can be aqueous extractum, also can be exsiccant extractum or powder, decide according to the needs of made preparation.
The present invention comprises that also said preparation comprises any dosage form of taking, as tablet, capsule, granule, oral liquid, pill, drop pill etc., most preferably drop pill with the Chinese medicine preparation of Chinese medicine extract of the present invention as the active constituents of medicine preparation.
Chinese medicine preparation of the present invention can add the medicine acceptable carrier as required by the technology preparation of galenic pharmacy routine during preparation.
Drop pill of the present invention can prepare by the following method:
Thick paste or dried powder that step c in the above method for preparing extractive is obtained add in the mixture of fused Macrogol 4000 or polyethylene glycol 6000 or Macrogol 4000 and polyethylene glycol 6000, add the thick paste that steps d obtains again, stir evenly, medicinal liquid is put in the drop pill machine material-storage jar, make drop pill with the drop pill machine, promptly.Preferably thick paste that step c is obtained or dried powder add in the mixture of fused an amount of Macrogol 4000 or polyethylene glycol 6000 or Macrogol 4000 and polyethylene glycol 6000, add the thick paste that the Radix Aucklandiae extracts again, stir evenly, medicinal liquid is put in the drop pill machine material-storage jar, insulation (80～85 ℃), splash into and be cooled in 5～10 ℃ of dimethicones with the speed of dripping of water dropper with 30～60 droplets/minute, with refrigerative drop pill, absorb coolant, drying, make 10000, promptly.
Dropping pill formulation through above method preparation, has tangible advantage, can remove most of impurity and keep the effective ingredient of each flavour of a drug to greatest extent by selected extraction, purification, technology such as refining, make the dried cream yield of medical material reach 5.0～6.5%, taking under the constant situation of crude drug amount, the drug administration amount reduces, active constituent content improves, by to using the drug extract that this technology makes and the pharmacodynamics test contrast of dropping pill formulation of making and XINKESHU PIAN agent, the result shows that the drug effect of dropping pill formulation is better.
Below by pharmacodynamic experiment data declaration beneficial effect of the present invention.
The medicine that the present invention uses prepares as preferable methods among the embodiment, but called after heart drop pills,
(1) but heart drop pills function of resisting myocardial ischemia research
Medicine and reagent
Medicine and reagent: but heart drop pills, lot number: 031011; The positive control drug XINKESHU PIAN, lot number 030912.Provide by Shandong China Wo Medicine Co, be mixed with desired concn with normal saline with preceding.Lignocaine, lot number 20030708, Beijing Yimin Pharmaceutical Co., Ltd. produces; Pentobarbital sodium, lot number 020919, the import packing of Beijing chemical reagents corporation; Red tetrazolium (TTC), lot number 1412B41, AMRESCO company product; Heparin sodium injection, lot number 030628, Chinese changzhou biochemical thousand red pharmaceutical Co. Ltds produce.Lactic acid dehydrogenase (LDH) test kit lot number 130071, creatine kinase (CK) test kit lot number 090143, Beijing Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd. produces.
Animal: the hybrid dog, the male and female dual-purpose, body weight: 17.5 ± 2.2kg, the first edge laboratory animal of virtue plant provides by Beijing.
Instrument: SC-3 type electric pulmotor (Shanghai Medical Equipment Factory); MFV-3200 type electromagnetic flowmeter (Japanese photoelectricity product); MP150 type physiograph (U.S. BIOPAC company); RMP6008 physiograph (Japanese photoelectricity product); R80 type blood viscosity instrument (Beijing Steellex Scientific Instrument Company).
Test method: the hybrid dog is divided into 5 groups at random, is respectively model group, positive controls (positive reference substance 160mg/kg), heavy dose of group (being subjected to test product 22mg/kg), middle dosage group (being subjected to test product 11mg/kg), small dose group (being subjected to test product 5.5mg/kg).Animal pentobarbital sodium 30mg/kg intravenous injection anesthesia separates left carotid, and intubate connects the pressure transducer recording blood pressure.Tracheal intubation is carried out assisted respiartion.The 4th intercostal is opened breast along the left side, seam pericardium bed.Separate aortic arch, place the electromagnetic flowmeter probe, measure cardiac output.Apex of the heart intubate connects pressure transducer, measures intraventricular pressure.Seam is put 16 epicardial leads of leading and is connected ecg amplifier, record visceral pericardium electrocardio.The abdominal part opening separates duodenum, is equipped with administrable.After every index that writes down is stablized 15min, adopt two steps ligation method ligation arteria coronaria left anterior descending branch, and administration in 5 minutes after formal ligation, model group is given the normal saline with equivalent.Respectively before ligation, ligation at once, 5,10,15,30,45,60,90,120,150,180min record visceral pericardium electrocardio calculates above each mapping point ST section constantly and raises total millivolt (mV) number and represent degree of myocardial ischemia, counts the ST section and raises to count greater than the mapping of 2mV and represent the myocardial ischemia scope.Respectively at 180min time point heart extracting blood before the pre-bundle and after the ligation, measure LDH and CK content in whole blood viscosity and the serum.It is dirty to core during off-test, on average is cut into five from the apex of the heart to ligation point, and 1%TTC dyeing is taken pictures, and picture is imported computer, calculates the ratio of infarct size and cutting cardiac muscular tissue area.
The result
By table 1-2 as seen, after the ligation of model group animal, electrocardio ST section is obviously raised; Tend towards stability by 5 minutes beginning animal cardiac muscle degree of ischemia after the visible ligation of table 1-1 simultaneously; In addition, the serology result confirm before the ligation with ligation after 3 hours, LDH and CK level obviously raise in the animal serum.Above result illustrates that all the dog myocardial infarction and ischemia model forms, and ligation after 5 minutes ischemia tend towards stability, can administration.
After the positive control drug 160mg/kg administration 10 minutes (be after the ligation 15 minutes), the scope of myocardial ischemia (table 1-1) begins to dwindle, simultaneously the order of severity of ischemia (table 1-2) also decreases, and wherein 30 minutes time point The above results and model group relatively have significant difference after the ligation.Cardiac muscle coloration result (table 1-3) and serology result (show 1-4, confirm also that 1-5) positive control drug can obviously alleviate the myocardial damage that coronary ligation causes.
After being subjected to reagent 22mg/kg administration, LDH, CK level and model group are approaching in the scope of each time point myocardial ischemia, ischemic myocardium ratio and the serum, and the ischemia order of severity and model group alleviate more to some extent.After being subjected to reagent 11mg/kg administration, as seen 10 minutes (after the ligation 15 minutes) beginning behind the self administration of medication, the scope and the order of severity of animal cardiac muscle ischemia all decrease, and after the ligation 30,60,120 minutes the time ischemia scope and model group significant difference is relatively arranged, after the ligation 10,30,60,120 minutes the time ischemia order of severity and model group significant difference is relatively arranged, ischemic myocardium ratio and serology result and model group more also have significant difference.Similar to the heavy dose group, be subjected to reagent 5.5mg/kg administration after, myocardial ischemia scope and model group are approaching, other index (the myocardial ischemia order of severity, ischemic myocardium ratio, Serum LDH, CK level) and model group more all decrease.
Electrocardio ST section presentation of results is subjected to reagent 11mg/kg and positive control drug 160mg/kg relatively, and the degree and the scope of each time point myocardial ischemia have notable difference.Among whole myocardium coloration result and the serology result, also has notable difference between two groups.
Conclusion
But heart drop pills 11mg/kg duodenal administration can obviously alleviate the dog acute myocardial ischemia damage that coronary ligation causes, and this effect is better than the effect after the positive control drug 160mg/kg administration.
But table 1-1. heart drop pills is to the influence of anesthetized dog myocardial ischemia scope (N-ST) (X ± SD)
| Dosage (mg/kg) | Number of animals | Minute (minute) | |||||||||||
| At once | 5 | 10 | 15 | 30 | 45 | 60 | 90 | 120 | 150 | 180 | |||
| Dosage low dose in the positive heavy dose of model | -- 160 22 11 5.5 | 6 5 5 5 5 | 13.3±2.6 14.4±1.1 12.0±7.8 12.0±2.9 14.6±4.6 | 14.8±1.5 14.4±1.5 13.4±0.9 14.0±1.6 15.2±0.8 | 14.3±1.5 15.0±1.2 13.6±0.9 12.6±3.4 15.0±1.7 | 14.3±1.7 13.0±2.5 12.0±0.0 12.4±3.6 14.2±2.0 | 15.3±1.5 12.0±3.3 * 10.6±0.5 10.4±4.2 * 14.6±1.7 | 15.5±1.0 15.2±0.8 11.6±0.5 12.0±2.8 14.4±1.1 | 14.8±1.5 14.2±1.8 11.8±0.4 11.6±2.5 * 14.8±1.3 | 15.0±1.2 12.4±3.4 12.0±0.0 12.0±2.5 14.6±1.1 | 15.8±0.5 12.4±3.0 10.4±1.3 10.0±3.2 * 15.2±1.3 | 16.0±0.0 11.6±4.4 10.8±0.5 12.2±2.6 15.0±1.2 | 16.0±0.0 9.6±5.5 9.0±0.0 9.0±4.7 14.8±1.3 |
Corresponding result constantly with model group compares,
*P＜0.05; But dosage, the corresponding result constantly with positive group of heavy dose of group compare P＜0.05 in the heart drop pills.
But the influence that table 1-2. heart drop pills is raised epicardial electrogram ST section due to the anesthetized dog myocardial ischemia (X ± SD, mV)
| Dosage (mg/kg) | Number of animals | Minute (minute) | |||||||||||
| At once | 5 | 10 | 15 | 30 | 45 | 60 | 90 | 120 | 150 | 180 | |||
| Dosage low dose in the positive heavy dose of model | -- 160 22 11 5.5 | 6 5 5 5 5 | 6.9±3.67 5.1±0.98 3.7±4.27 3.5±1.78 3.7±2.17 | 11.7±5.95 6.4±1.71 4.8±2.71 5.1±1.90 6.3±2.33 | 11.4±5.98 6.6±1.53 4.0±3.06 4.2±2.02 * 6.1±2.32 | 10.9±6.83 5.2±2.95 4.5±2.20 4.7±2.10 5.5±2.12 | 10.1±5.26 4.1±2.73 * 2.6±2.20 3.1±3.39 * 6.2±2.98 | 10.8±6.01 4.9±1.14 3.5±2.41 4.1±2.38 6.6±3.08 | 10.7±5.83 4.4±2.31 3.3±2.31 3.9±1.53 * 7.0±3.41 | 11.0±5.72 4.0±3.50 3.1±2.61 3.7±1.67 6.9±2.88 | 12.0±4.35 4.5±4.33 2.2±2.88 2.8±1.84 * 6.5±2.36 | 14.7±3.22 4.3±4.49 3.3±3.00 3.8±1.76 5.9±1.77 | 14.3±4.00 3.6±4.68 3.0±2.50 3.2±2.76 6.3±3.06 |
Corresponding result constantly with model group compares,
*P＜0.05; But dosage, the corresponding result constantly with positive group of heavy dose of group compare P＜0.05 in the heart drop pills.
But table 1-3. heart drop pills is to the influence of anesthetized dog coronary ligation myocardial infarct size after 3 hours (X ± SD)
| Dosage (mg/kg) | Number of animals | Ischemia scope (%) | |
| Dosage low dose in the positive heavy dose of model | -- 160 22 11 5.5 | 6 5 5 5 5 | 0.035±0.013 0.014±0.011 * 0.011±0.046 0.012±0.005 * 0.020±0.020 |
Compare with model group,
*P＜0.05; But dosage, heavy dose of group are compared P＜0.05 with positive group in the heart drop pills
But table 1-4. heart drop pills is to the influence of LDH level in the serum before and after the anesthetized dog coronary ligation (X ± SD)
| Number of animals | Dosage (mg/kg) | Before the ligation | After the ligation 3 hours | Difference before and after the ligation | |
| Dosage low dose in the positive heavy dose of model | 6 5 5 5 5 | -- 160 22 11 5.5 | 74.8±23.6 76.8±11.5 83.0±50.9 72.2±22.7 79.2±26.3 | 161.3±21.4 126.8±23.6 * 115.4±59.8 122.0±14.0 * 127.2±26.4 | 86.5±23.6 50.0±18.1 * 35.4±24.0 45.8±20.1 * 51.0±30.3 |
Compare with model group,
*P＜0.05; But dosage, heavy dose of group are compared P＜0.05 with positive group in the heart drop pills
But table 1-5. heart drop pills is to the influence of CK level in the serum before and after the anesthetized dog coronary ligation (X ± SD)
| Number of animals | Dosage (mg/kg) | Before the ligation | After the ligation 3 hours | Difference before and after the ligation | |
| Dosage low dose in the positive heavy dose of model | 6 5 5 5 5 | -- 160 22 11 5.5 | 302.8±143.5 324.4±125.2 387.2±95.6 403.8±88.9 427.6±121.1 | 1571.5±741.9 766.4±257.6 * 675.9±237.5 786.0±207.9 * 772.4±391.8 | 1268.7±753.7 442.0±241.7 * 288.7±147.1 382.2±167.2 * 460.8±210.3 |
Compare with model group,
*P＜0.05; But dosage, heavy dose of group are compared P＜0.05 with positive group in the heart drop pills
(2) but heart drop pills is treated ARR experimental study
Material and method
Medicine and reagent: but heart drop pills, lot number: 031011; The positive control drug XINKESHU PIAN, lot number 030912.Provide by Shandong China Wo Medicine Co, be mixed with desired concn with normal saline with preceding.Pentobarbital sodium, lot number 030919, Beijing chemical reagents corporation;
Heparin sodium injection, lot number 030128, Chinese changzhou biochemical thousand red pharmaceutical factories produce.
Propylthiouracil: morning sunlight pharmaceutical factory of The 2nd Army Medical College produces, lot number: 031103.
Aconitine is produced by Merck company
Urethanes: China Medicine (Group) Shanghai Chemical Reagent Co.,, lot number: 020342.
Pentobarbital: import packing, Shanghai chemical reagent purchasing and supply station packing.Lot number: 021122.
Animal
The Wistar rat, Shandong Traditional Chinese Medicine University's animal center provides.
Instrument
MP150 type physiograph (U.S. BIOPAC company); Rat blood pressure analyzer Tian Jinjin defends Electronics Factory and produces.Kenz ECG103 electrocardiograph, Japan produces.
Test method and result
1, but heart drop pills is to the influence of ischemic arrhythmia
Get 60 of male rats, body weight 250 ± 20g is with 20% urethanes 1g/kg, behind the intraperitoneal injection of anesthesia, it is fixing that rat faces upward the position, record II lead electrocardiogram, reject the abnormal rat of electrocardiogram, cut off the 3-4 rib, open breast and cut off pericardium along left border of sternum, expose heart, the ligation of left anterior descending coronary artery root threading, promptly prop up chamber, a 2mm place ligation coronary artery left side below pulmonary conus and left auricle root, and heart is put back to the thoracic cavity, overstock the thoracic cavity gently, extrude gas in the thoracic cavity.Measuring the animal electrocardiogram after 15 minutes in ligation then, is observation index with ∑ S-T, as myocardial ischemia electrocardiogram after the ligation.Each rat difference duodenal administration once then, XINKESHU PIAN low dose, middle dosage, heavy dose, XINKESHU PIAN and normal saline, administration volume are 0.5ml/100g, different time sections is measured electrocardiogram, Electrocardiographic difference after 5h animal electrocardiogram and the ligation after the record analysis administration after administration; Raise as the arrhythmia index to occur the ST section on the electrocardiogram, result of the test sees Table 2-1,
But table 2-1 heart drop pills is to (the X ± SD) of the Electrocardiographic influence of acute myocardial ischemia due to the rat coronary ligation
| Group | Dosage (mg/kg) | ∑ S-T (mv) before the medicine | ∑ S-T (mv) behind the medicine | Before the medicine-medicine after (mv) |
| The heavy dose of group of dosage group XINKESHU PIAN group in the normal saline small dose group | Isometric(al) 5.5 11 22 160 | 9.21±2.34 9.23±3.21 8.98±2.76 9.43±3.27 9.23±2.46 | 9.22±3.11 8.22±2.47 6.61±2.34 ※ 5.89±2.13 ※※ 6.56±3.01 ※ | -0.02±0.02 1.02±0.52 ※※ 2.38±0.54 ※※ 3.54±0.89 ※※ 2.67±0.65 ※※ |
Compare ※ p＜0.05, ※ ※ p＜0.01 with the normal saline group; But dosage group and XINKESHU PIAN group compare P＜0.05 in the heart drop pills, but the heavy dose of group of heart drop pills compares P＜0.01 with the XINKESHU PIAN group.
From test as can be seen: XINKESHU PIAN and drop pill all can obviously reduce raising of rat electrocardiogram S-T, and the reduction amplitude meets dose-effect relationship, but but heart drop pills effect is better than XINKESHU PIAN, be significant difference.
2, but heart drop pills brings out the influence of rat ventricular to aconitine
Get 50 male and female half and half of rat, body weight 220-250g is divided into 5 groups at random.But continuous irrigation stomach heart drop pills low dose, middle dosage, heavy dose and XINKESHU PIAN then, successive administration 7 days.After the last administration 1 hour, lumbar injection urethane 1g/kg, it is fixing that rat faces upward the position, normal ECG is described, record II lead electrocardiogram is rejected the abnormal rat of electrocardiogram, and sublingual vein has pushed away aconitine 20ug/kg in 10 seconds again, observe the time of rat ventricular appearance and the time that arrhythmia is kept immediately, result of the test sees Table 2.
But table 2-2, heart drop pills bring out the influence (X ± SD) of rat ventricular to aconitine
| Group | Dosage (mg/kg) | Arrhythmia time of occurrence (min) | The arrhythmia persistent period (min) |
| The heavy dose of group of dosage group XINKESHU PIAN group in the normal saline group small dose group | -- 5.5 11 22 160 | 1.86±0.87 2.55±1.11 3.54±1.43 ※※ 4.38±1.54 ※※ 2.76±1.07 ※ | 132±24 113±25 109±19 ※ 98±16 ※※ 113±19 ※ |
Compare ※ p＜0.05, ※ ※ p＜0.01 with the normal saline group; But dosage group and XINKESHU PIAN group compare P＜0.05 in the heart drop pills, but the heavy dose of group of heart drop pills compares P＜0.01 with the XINKESHU PIAN group.
From test as can be seen: XINKESHU PIAN and drop pill can both postpone the time that arrhythmia occurs, and shorten the time that arrhythmia is kept, and have tangible antiarrhythmic effect, but but heart drop pills effect is better than tablet, have significant difference.
Conclusion:
But heart drop pills can obviously improve the myocardial ischemia degree of arrhythmia; Obviously postpone the arrhythmia time of occurrence that aconitine causes, shorten aconitine institute's proarrhythmia persistent period.But heart drop pills arrhythmia effect is better than XINKESHU PIAN, has significant difference
(3) but heart drop pills is treated hypertensive experimental data and study
Material and reagent
But heart drop pills, Shandong China Wo Medicine Co, lot number: 031011
Animal dosage is determined: drop pill is made into 3%, 6%, 12% concentration respectively with distilled water, and the administration volume is 1ml/kg, then low dose of 5 times of being equivalent to people's consumption, and 10 times of middle dosage behaviour consumption, heavy dose is 20 times of people's consumption.The normal saline group is irritated the isometric normal saline of stomach.
XINKESHU PIAN: provide lot number by Shandong China Wo Medicine Co: 030912
Lignocaine, lot number 031108, Beijing Yimin Pharmaceutical Co., Ltd. produces;
Pentobarbital sodium, lot number 030919, Beijing chemical reagents corporation;
Urethanes: China Medicine (Group) Shanghai Chemical Reagent Co.,, lot number: 020342.
Animal
The Wistar rat, Shandong Traditional Chinese Medicine University's animal center provides.
Instrument
MP150 type physiograph (U.S. BIOPAC company); RMP6008 physiograph (Japanese photoelectricity product).
Test method and result
Get 60 of healthy male rats, body weight 250 ± 20g, lumbar injection pentobarbital sodium 40mg/kg, be fixed on the big rat holder, cut off dorsal body setae, iodine tincture and alcohol disinfecting, cover ambut towel,, cut skin downwards from the rib lower edge in left of spine, peel off muscle, expose kidney, separate renal artery, ligation renal artery after putting a diameter 0.2mm thin copper wire on the renal artery is extracted copper wire out, skin suture, put back to mouse cage after the sterilization, this is for forming two kidneys, one folder renal hypertension.Rat blood pressure is measured with the rat blood pressure analyzer in the back all around, surveys twice continuously for every, with twice meansigma methods as this Mus blood pressure.Be higher than the rat of 25kpa as Hypertensive Rats with systolic pressure, with Hypertensive Rats according to blood pressure at random rat be divided into 5 groups: the heart can relax small dose group (3%), middle dosage group (6%), heavy dose of group (12%) and negative control group (normal saline group), positive controls (XINKESHU PIAN group), 10 every group.All animals gastric infusion all then, the administration volume is 1ml/100g, 1/ day, continuous 30 days, respectively at 2 weeks of administration, 3 weeks, 4 all replication rat blood pressures, result of the test saw Table 3-1.
Table 3-1: but heart drop pills is to the influence of renal hypertensive rat blood pressure (x ± SD)
| Group | Dosage (g/kg) | Blood pressure (kpa) before the medicine | 2 weeks day (kpa) behind the medicine | 3 weeks (kpa) behind the medicine | 4 weeks (kpa) behind the medicine |
| The heavy dose of group of dosage group XINKESHU PIAN group in the normal saline group small dose group | -- 5.5 11 22 160 | 29.5±2.1 28.6±1.9 29.6±1.3 28.8±2.3 28.3±1.9 | 30.5±2.5 29.6±2.1 26.4±1.6 ※ 27.6±1.8 ※※ 28.7±1.7 | 29.9±1.9 28.5±1.5 26.9±1.7 ※ 27.3±1.6 ※※ 28.3±1.8 | 30.9±2.3 28.3±1.6 ※ 25.6±1.9 ※※ 26.1±1.6 ※※ 27.8±1.9 ※※ |
Compare ※ p＜0.05, ※ ※ p＜0.01 with the normal saline group; But dosage, heavy dose of group are compared P＜0.05 with positive group in the heart drop pills
Result of the test shows: but heart drop pills can obviously reduce hypertensive rat blood pressure, the reduction amplitude becomes significantly dose-effect relationship with dosage, and strengthens to some extent with the prolongation hypotensive effect of administration time, and antihypertensive effect is better than the XINKESHU PIAN group, has significant difference.
Conclusion: but heart drop pills has significant difference being better than XINKESHU PIAN aspect the reduction hypertensive rat blood pressure.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1:
[prescription]: Radix Puerariae 500g Fructus Crataegi 400g Radix Salviae Miltiorrhizae 400g Radix Notoginseng 20g Radix Aucklandiae 20g
[method for making] above five tastes medical material, Fructus Crataegi, Radix Puerariae, Radix Notoginseng are measured 80% alcohol reflux 2 times for 3 times with each medical material, and 1 hour for the first time, 1 hour for the second time, merge alcohol extract, reclaim ethanol, filtration, filtrate for later use.Radix Salviae Miltiorrhizae extracts three times, adds 95% alcohol reflux 1 hour of 3 times of amounts of medical material for the first time, filters, and filtrate recycling ethanol is to there not being the alcohol flavor; 80% alcohol reflux 1 hour that adds for the second time 3 times of amounts, filter, reclaim ethanol: the water that adds 3 times of amounts of medical material for the third time refluxed 1 hour, filter, merging filtrate is evaporated to the clear paste that relative density is 1.06 (80 ℃ of surveys) jointly with above-mentioned standby filtrate, with 60% alcoholic acid ethyl acetate extraction of equimultiple 3 times, combining extraction liquid, and concentrating under reduced pressure becomes thick paste.Radix Aucklandiae powder is broken into coarse powder, makes solvent according to percolation under fluid extract and the extractum item (" appendix 20 of Chinese pharmacopoeia version in 2000) with 95% ethanol, soaks after 24 hours, and percolation, percolate reclaim the ethanol concentrating under reduced pressure and become thick paste.Above-mentioned thick paste is added in the fused an amount of polyethylene glycol 6000, stir evenly, medicinal liquid is put in the drop pill machine material-storage jar, insulation (80～85 ℃) splashes into 30 droplets/minute droplet speed with water dropper and to be cooled in 5 ℃ of dimethicones, with refrigerative drop pill, absorb coolant, drying is made 10000, promptly.
Embodiment 2:
[prescription]: Radix Puerariae 800g Fructus Crataegi 800g Radix Salviae Miltiorrhizae 800g Radix Notoginseng 60g Radix Aucklandiae 60g
[method for making] above five tastes medical material, Fructus Crataegi, Radix Puerariae, Radix Notoginseng are measured 40% alcohol reflux 2 times for 10 times with each medical material, and 3 hours for the first time, 3 hours for the second time, merge alcohol extract, reclaim ethanol, filtration, filtrate for later use.Radix Salviae Miltiorrhizae extracts three times, adds 60% alcohol reflux 3 hours of 15 times of amounts of medical material for the first time, filters, and filtrate recycling ethanol is to there not being the alcohol flavor; Add for the second time 20% alcohol reflux 3 hours of 15 times of amounts, filter, reclaim ethanol; The water that adds 15 times of amounts of medical material for the third time refluxed 3 hours, filter, merging filtrate is evaporated to the clear paste that relative density is 1.12 (80 ℃ of surveys) jointly with above-mentioned standby filtrate, with the ethyl acetate extraction of equimultiple 6 times, combining extraction liquid, and concentrating under reduced pressure becomes thick paste, in 80 ℃ of dryings 8 hours, pulverizes, cross 80 mesh sieves, make dried powder.Radix Aucklandiae powder is broken into coarse powder, makes solvent according to percolation under fluid extract and the extractum item (" appendix 20 of Chinese pharmacopoeia version in 2000) with 60% ethanol, soaks after 24 hours, and percolation, percolate reclaim the ethanol concentrating under reduced pressure and become thick paste.Dried powder is added in the fused an amount of Macrogol 4000, add the thick paste that the Radix Aucklandiae extracts again, stir evenly, medicinal liquid is put in the drop pill machine material-storage jar, insulation (80～85 ℃), splash into and be cooled in 10 ℃ of dimethicones with the speed of dripping of water dropper with 60 droplets/minute, with refrigerative drop pill, absorb coolant, drying, make 10000, promptly.
Embodiment 3:
Radix Puerariae 600g Fructus Crataegi 600g Radix Salviae Miltiorrhizae 600g Radix Notoginseng 40g Radix Aucklandiae 40g
[method for making] above five tastes medical material, Fructus Crataegi, Radix Puerariae, Radix Notoginseng are measured 80% alcohol reflux 2 times for 8 times with each medical material, and 1 hour for the first time, 1 hour for the second time, merge alcohol extract, reclaim ethanol, filtration, filtrate for later use.Radix Salviae Miltiorrhizae extracts three times, adds 95% alcohol reflux 1 hour of 12 times of amounts of medical material for the first time, filters, and filtrate recycling ethanol is to there not being the alcohol flavor; Add for the second time 80% alcohol reflux 1 hour of 10 times of amounts, filter, reclaim ethanol; The water that adds 10 times of amounts of medical material for the third time refluxed 1 hour, filter, merging filtrate is evaporated to the clear paste that relative density is 1.08 (80 ℃ of surveys) jointly with above-mentioned standby filtrate, with 30% alcoholic acid ethyl acetate extraction of equimultiple 3 times, combining extraction liquid, and concentrating under reduced pressure becomes thick paste, in 60 ℃ of dryings 8 hours, pulverizes, cross 80 mesh sieves, make dried powder.Radix Aucklandiae powder is broken into coarse powder, makes solvent according to percolation under fluid extract and the extractum item (" appendix 20 of Chinese pharmacopoeia version in 2000) with 90% ethanol, soaks after 24 hours, and percolation, percolate reclaim the ethanol concentrating under reduced pressure and become thick paste.Dried powder is added in the fused an amount of polyethylene glycol 6000, add the thick paste that the Radix Aucklandiae extracts again, stir evenly, medicinal liquid is put in the drop pill machine material-storage jar, insulation (80～85 ℃), splash into and be cooled in 5 ℃ of dimethicones with the speed of dripping of water dropper with 30 droplets/minute, with refrigerative drop pill, absorb coolant, drying, make 10000, promptly.
Embodiment 4:
Radix Puerariae 500g Fructus Crataegi 400g Radix Salviae Miltiorrhizae 400g Radix Notoginseng 20g Radix Aucklandiae 20g
[method for making] above five tastes medical material, Fructus Crataegi, Radix Puerariae, Radix Notoginseng are measured 80% alcohol reflux 2 times for 3 times with each medical material, and 1 hour for the first time, 1 hour for the second time, merge alcohol extract, reclaim ethanol, filtration, filtrate for later use.Radix Salviae Miltiorrhizae extracts three times, adds 95% alcohol reflux 1 hour of 3 times of amounts of medical material for the first time, filters, and filtrate recycling ethanol is to there not being the alcohol flavor; Add for the second time 80% alcohol reflux 1 hour of 3 times of amounts, filter, reclaim ethanol; The water that adds 3 times of amounts of medical material for the third time refluxed 1 hour, filtered merging filtrate, be evaporated to the clear paste that relative density is 1.06 (80 ℃ of surveys) jointly with above-mentioned standby filtrate, with 60% alcoholic acid ethyl acetate extraction of equimultiple 3 times, combining extraction liquid, and concentrating under reduced pressure becomes thick paste.Radix Aucklandiae powder is broken into coarse powder, makes solvent according to percolation under fluid extract and the extractum item (" appendix 20 of Chinese pharmacopoeia version in 2000) with 95% ethanol, soaks after 24 hours, and percolation, percolate reclaim the ethanol concentrating under reduced pressure and become thick paste.With the thick paste mixing drying under reduced pressure of dried powder and Radix Aucklandiae extraction, granulate, add starch, the ethanol mixing adds Pulvis Talci, the magnesium stearate tabletting, the bag film-coat is made 1000 tablets of tablets, promptly.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410080445 CN1291735C (en) | 2004-10-10 | 2004-10-10 | A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410080445 CN1291735C (en) | 2004-10-10 | 2004-10-10 | A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616060A CN1616060A (en) | 2005-05-18 |
| CN1291735C true CN1291735C (en) | 2006-12-27 |
Family
ID=34765622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410080445 Expired - Lifetime CN1291735C (en) | 2004-10-10 | 2004-10-10 | A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291735C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006769A (en) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103720810A (en) * | 2012-10-16 | 2014-04-16 | 吉林吉春制药股份有限公司 | Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine |
| CN102988478B (en) * | 2013-01-05 | 2014-11-05 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN105395637A (en) * | 2015-12-23 | 2016-03-16 | 济南陆枋志合信息技术有限公司 | Drug for treating heart disease |
| CN105434583A (en) * | 2015-12-29 | 2016-03-30 | 山东沃华医药科技股份有限公司 | Semi-bionic preparation method for Xinkeshu preparations |
| CN106236874A (en) * | 2016-08-29 | 2016-12-21 | 河北国金药业有限责任公司 | Pharmaceutical composition is as the application in preparation treatment cerebrovascular disease and complication medicine thereof |
| CN108279272B (en) * | 2017-01-06 | 2020-11-27 | 山东沃华医药科技股份有限公司 | Method for simultaneously determining contents of multiple components in Xinkeshu tablet |
-
2004
- 2004-10-10 CN CN 200410080445 patent/CN1291735C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006769A (en) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1616060A (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006838B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1291735C (en) | A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain | |
| CN1262299C (en) | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method | |
| CN103006769B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN105434583A (en) | Semi-bionic preparation method for Xinkeshu preparations | |
| CN1840166A (en) | Wendan decoction modern traditional Chinese medicine oral preparation and production method thereof | |
| CN1206236C (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
| CN1285358C (en) | Medicinal composition, preparation and quality control thereof | |
| CN1297288C (en) | Medicine for treating cardiovascular disease, and its prepn. method | |
| CN1775261A (en) | Mingmu-Dihuang preparation and new preparing method | |
| CN102988478B (en) | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1544429A (en) | Bee glue flavone extract preparation method, pharmaceutical preparation and its new medical uses | |
| CN105999195A (en) | Preparation method of radix codonopsis, ramulus cinnamomi and poria cocos preparation | |
| CN100396279C (en) | A kind of traditional Chinese medicine preparation for treating arrhythmia and preparation method thereof | |
| CN1679676A (en) | Six-component saf-flower drops and preparation thereof | |
| CN1839934A (en) | Chinese traditional medicine and its preparation method and use | |
| CN1895367A (en) | Chinese-medicinal preparation for treating coronary heart disease and angina cordis and its preparation | |
| CN1267126C (en) | Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN1258365C (en) | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process | |
| CN1850264A (en) | Safflower preparation for treating wound and new preparing method | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN100341558C (en) | Traditional Chinese medicine for treating coronary heat disease and angina cordis, and its prepn. method | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1965849A (en) | Composition extracted from Chinese medicinals for treating coronary heart disease and method for preparing ingredients thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061227 |